CAPRICOR THERAPEUTICS, INC. (CAPR) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -135.16M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 99.73M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-135.16M | (m) | (m) | $99.73M | (m) | (m) |
| 2026-03-31 | $-119.93M | (m) | (m) | $92.92M | (m) | (m) |
| 2025-12-31 | $-108.14M | $0.00 | (m) | $84.45M | (m) | (m) |
| 2025-09-30 | $-86.68M | (m) | (m) | $75.88M | (m) | (m) |
| 2025-06-30 | $-73.41M | (m) | (m) | $67.33M | (m) | (m) |
| 2025-03-31 | $-57.28M | (m) | (m) | $57.78M | (m) | (m) |
| 2024-12-31 | $-42.56M | $22.27M | (m) | $49.97M | (m) | -191.13% |
| 2024-09-30 | $-36.15M | $23.23M | (m) | $45.35M | (m) | -155.62% |
| 2024-06-30 | $-30.00M | $27.15M | (m) | $43.57M | (m) | -110.50% |
| 2024-03-31 | $-26.16M | $27.10M | (m) | $39.89M | (m) | -96.53% |
| 2023-12-31 | $-24.08M | $25.18M | (m) | $36.45M | (m) | -95.63% |
| 2023-09-30 | $-30.86M | $14.05M | (m) | $32.74M | (m) | -219.67% |
| 2023-06-30 | $-30.48M | $9.46M | (m) | $28.22M | (m) | -322.31% |
| 2023-03-31 | $-30.05M | (m) | (m) | $24.36M | (m) | (m) |
| 2022-12-31 | $-29.70M | $2.55M | (m) | $21.82M | (m) | -1163.93% |
| 2022-09-30 | $-28.01M | $1.59M | (m) | $19.85M | (m) | -1759.94% |
| 2022-06-30 | $-25.85M | (m) | (m) | $16.86M | (m) | (m) |
| 2022-03-31 | $-23.61M | (m) | (m) | $15.39M | (m) | (m) |
| 2021-12-31 | $-20.94M | $244.90K | (m) | $13.57M | (m) | -8549.86% |
| 2021-09-30 | $-18.74M | $302.73K | (m) | $12.05M | (m) | -6190.16% |
| 2021-06-30 | $-18.34M | $319.59K | (m) | $12.17M | (m) | -5738.23% |
| 2021-03-31 | $-16.74M | $165.37K | (m) | $10.60M | (m) | -10124.72% |
| 2020-12-31 | $-13.69M | $310.25K | (m) | $8.46M | (m) | -4412.56% |
| 2020-09-30 | $-10.99M | $474.52K | (m) | $6.54M | (m) | -2316.61% |
| 2020-06-30 | $-8.71M | $599.73K | (m) | $4.77M | (m) | -1451.72% |
| 2020-03-31 | $-7.28M | $960.22K | (m) | $4.49M | (m) | -758.60% |
| 2019-12-31 | $-7.73M | $1.01M | (m) | $5.14M | (m) | -769.52% |
| 2019-09-30 | $-9.56M | (m) | (m) | $7.16M | (m) | (m) |
| 2019-06-30 | $-12.10M | (m) | (m) | $9.44M | (m) | (m) |
| 2019-03-31 | $-14.20M | (m) | (m) | $11.18M | (m) | (m) |
| 2018-12-31 | $-15.33M | $1.67M | (m) | $12.07M | (m) | -917.04% |
| 2018-09-30 | $-15.30M | $1.50M | (m) | $11.74M | (m) | -1020.73% |
| 2018-06-30 | $-13.77M | $1.59M | (m) | $10.47M | (m) | -864.19% |
| 2018-03-31 | $-12.98M | $2.19M | (m) | $10.21M | (m) | -594.03% |
| 2017-12-31 | $-12.86M | $2.67M | (m) | $10.77M | (m) | -482.40% |
| 2017-09-30 | $-12.50M | $3.10M | (m) | $10.91M | (m) | -403.40% |
| 2017-06-30 | $-15.10M | $3.53M | (m) | $13.78M | (m) | -427.58% |
| 2017-03-31 | $-16.33M | $3.66M | (m) | $14.96M | (m) | -445.68% |
| 2016-12-31 | $-16.98M | $4.00M | (m) | $16.04M | (m) | -424.56% |
| 2016-09-30 | $-17.35M | $4.22M | (m) | $16.71M | (m) | -411.57% |
| 2016-06-30 | $-14.96M | $4.78M | (m) | $15.17M | (m) | -312.73% |
| 2016-03-31 | $-13.41M | $4.94M | (m) | $14.29M | (m) | -271.15% |
| 2015-12-31 | $-12.61M | $5.52M | (m) | $13.76M | (m) | -228.57% |
| 2015-09-30 | $-11.19M | $5.80M | (m) | $13.01M | (m) | -193.12% |
| 2015-06-30 | $-9.83M | $5.78M | (m) | $11.78M | (m) | -169.95% |
| 2015-03-31 | $-8.25M | $5.53M | (m) | $10.22M | (m) | -149.06% |
| 2014-12-31 | $-6.02M | $4.79M | (m) | $7.79M | (m) | -125.72% |
| 2014-09-30 | $-6.51M | (m) | (m) | $6.89M | (m) | (m) |
| 2014-06-30 | $-6.52M | (m) | (m) | $5.93M | (m) | (m) |
| 2014-03-31 | $-6.66M | (m) | (m) | $5.38M | (m) | (m) |
| 2013-12-31 | $-6.90M | (m) | (m) | $5.20M | (m) | (m) |
| 2013-09-30 | $-1.36M | $0.00 | (m) | $176.99K | (m) | (m) |
| 2013-06-30 | $-1.64M | $0.00 | (m) | $325.25K | (m) | (m) |
| 2013-03-31 | $-2.00M | $0.00 | (m) | $621.18K | (m) | (m) |
| 2012-12-31 | $-2.44M | $195.50K | (m) | $1.02M | (m) | -1248.15% |
| 2012-09-30 | $-3.79M | $391.00K | (m) | $2.32M | (m) | -968.18% |
| 2012-06-30 | $-4.37M | $1.20M | (m) | $3.61M | (m) | -362.59% |
| 2012-03-31 | $-4.47M | $1.55M | (m) | $3.98M | (m) | -288.48% |
| 2011-12-31 | $-4.90M | $1.35M | (m) | $4.14M | (m) | -361.70% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-6.29M | (m) | (m) | $4.08M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |